MDNA
Price:
$0.157
Market Cap:
$0
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a ...[Read more]
Industry
Biotechnology
IPO Date
2017-11-13
Stock Exchange
NASDAQ
Ticker
MDNA
According to Medicenna Therapeutics Corp.’s latest financial reports and current stock price. The company's current Current Ratio is 7.49. This represents a change of -24.24% compared to the average of 9.89 of the last 4 quarters.
The mean historical Current Ratio of Medicenna Therapeutics Corp. over the last ten years is 5.92. The current 7.49 Current Ratio has changed 12.55% with respect to the historical average. Over the past ten years (40 quarters), MDNA's Current Ratio was at its highest in in the June 2016 quarter at 80.29K. The Current Ratio was at its lowest in in the December 2015 quarter at 0.
Average
5.92
Median
2.21
Minimum
0.68
Maximum
20.85
Discovering the peaks and valleys of Medicenna Therapeutics Corp. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 878.65%
Maximum Annual Current Ratio = 20.85
Minimum Annual Increase = -50.78%
Minimum Annual Current Ratio = 0.68
Year | Current Ratio | Change |
---|---|---|
2023 | 9.57 | 7.29% |
2022 | 8.92 | -13.04% |
2021 | 10.26 | -50.78% |
2020 | 20.85 | 878.65% |
2019 | 2.13 | -6.76% |
2018 | 2.29 | 16.75% |
2017 | 1.96 | 21.47% |
2016 | 1.61 | 73.46% |
2015 | 0.93 | 36.97% |
The current Current Ratio of Medicenna Therapeutics Corp. (MDNA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
9.59
5-year avg
10.35
10-year avg
5.92
Medicenna Therapeutics Corp.’s Current Ratio is less than Achilles Therapeutics plc (8.24), greater than Checkpoint Therapeutics, Inc. (0.26), greater than Cue Biopharma, Inc. (2.06), greater than Pieris Pharmaceuticals, Inc. (3.95), less than Eliem Therapeutics, Inc. (60.41), less than Ikena Oncology, Inc. (18.22), greater than Ovid Therapeutics Inc. (5.73), greater than Connect Biopharma Holdings Limited (4.99), less than Edgewise Therapeutics, Inc. (30.24), less than Protara Therapeutics, Inc. (16.33), greater than Vaccinex, Inc. (0.42), greater than Monopar Therapeutics Inc. (6.59), greater than Miromatrix Medical Inc. (3.46), greater than Surrozen, Inc. (6.96), less than Passage Bio, Inc. (7.67), less than Magenta Therapeutics, Inc. (14.64), greater than TRACON Pharmaceuticals, Inc. (0.66), greater than Invivyd, Inc. (4.71), greater than Aptevo Therapeutics Inc. (1.77), less than Werewolf Therapeutics, Inc. (12.13), greater than Oncorus, Inc. (1.50), greater than SAB Biotherapeutics, Inc. (5.24), greater than Akari Therapeutics, Plc (0.58),
Company | Current Ratio | Market cap |
---|---|---|
8.24 | $29.58M | |
0.26 | $93.07M | |
2.06 | $28.70M | |
3.95 | $22.50M | |
60.41 | $495.57M | |
18.22 | $81.56M | |
5.73 | $72.39M | |
4.99 | $68.88M | |
30.24 | $1.64B | |
16.33 | $38.27M | |
0.42 | $9.73M | |
6.59 | $8.41M | |
3.46 | $92.95M | |
6.96 | $29.60M | |
7.67 | $43.48M | |
14.64 | $42.44M | |
0.66 | $194.57K | |
4.71 | $97.23M | |
1.77 | $3.11M | |
12.13 | $88.28M | |
1.50 | $3.14M | |
5.24 | $26.21M | |
0.58 | $35.02M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Medicenna Therapeutics Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Medicenna Therapeutics Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Medicenna Therapeutics Corp.'s Current Ratio?
How is the Current Ratio calculated for Medicenna Therapeutics Corp. (MDNA)?
What is the highest Current Ratio for Medicenna Therapeutics Corp. (MDNA)?
What is the 3-year average Current Ratio for Medicenna Therapeutics Corp. (MDNA)?
What is the 5-year average Current Ratio for Medicenna Therapeutics Corp. (MDNA)?
How does the current Current Ratio for Medicenna Therapeutics Corp. (MDNA) compare to its historical average?